A Phase 2 interventional study of PCI-32765 in B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and Diffuse Well-differentiated Lymphocytic Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-27.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 16th largest by enrollment, is one of 3 that started in 2010, is one of 43 in phase 2, and was the 2nd registered.
2,038 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
Paolo Ghia · Sites in Italy
Ages 18–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–75
Jeanette Lundin · Sites in Norway, Sweden
Ages 18+
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 51 · Phase 3 15 · Phase 4 1
First in 2010; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 199 is above the median of 39 across 1,605 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 44 across the 83 interventional studies. Of the 44 that completed or were terminated, 26 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 83 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pharmacyclics LLC., one of the names counted as AbbVie. Under that name alone:
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie: 3 open now, 11 under way, 2 of them phase 3. Of 38 finished, 18 (47%) have results posted.
Among the 51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie, this one is the 9th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2010, is one of 11 in phase 2, and was the 10th registered.
AbbVie’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2004.
6 of the studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT03513562Ohio State University Comprehensive Cancer CenterVenetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | 2026-12-31 |
| NCT03153202Joshua BrodyStudy to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | 2027-04 |
| NCT03960840Novartis PharmaceuticalsPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | 2027-06-30 |
| NCT02756897M.D. Anderson Cancer CenterVenetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia | 2027-07-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among AbbVie’s 51 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the long-term safety of a fixed-dose, daily regimen of PCI-32765 PO in subjects with B cell lymphoma or chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PCI-32765
Dose based on parent protocol
Number of Subjects With Adverse Events
Subjects were to receive ibrutinib once daily at the dose level the subject was receiving in the parent study until disease progression or unacceptable toxicity. The study included Screening, Treatment (from the first dose until study drug discontinuation), and Follow-up Phases.
Time frame: 30 days after last dose of study drug, continue up to 6 months
Progressive Disease (PD)
A progressive disease confirmed by a CT scan.
Time frame: 30 days after last dose of study drug, continue up to 6 months
Death Event
All death events are due to AE, progressive disease, and other reasons.
Time frame: 30 days after last dose of study drug
Documented Responses
Investigator-assessed responses were summarized descriptively for subjects with CLL/SLL and listed for subjects with other NHLs based on the efficacy population.
Time frame: 30 days after last dose of study drug, continue up to 6 months
27 July 2010 (the first Patient enrolled) to 31 March 2016 (the Last patient enrolled), Study was approved on June 2010.
| Milestone | A LONG-TERM SAFETY STUDY OF BRUTON'S TYROSINE KINASE (BTK) INH |
|---|---|
| Started | 199 |
| Completed | 106 |
| Not completed | 93 |
Subjects were to receive ibrutinib once daily at the dose level the subject was receiving in the parent study until disease progression or unacceptable toxicity. The study included Screening, Treatment (from the first dose until study drug discontinuation), and Follow-up Phases.
| Participants | A LONG-TERM SAFETY STUDY OF BRUTON'S TYROSINE KINASE (BTK) INH |
|---|---|
| Number of Subjects With Adverse Events | 199 |
A progressive disease confirmed by a CT scan.
| Participants | IBRUTINIB/PCI-32765 |
|---|---|
| Progressive Disease (PD) | 70 |
All death events are due to AE, progressive disease, and other reasons.
| Participants | IBRUTINIB/PCI-32765 |
|---|---|
| Death Event | 42 |
Investigator-assessed responses were summarized descriptively for subjects with CLL/SLL and listed for subjects with other NHLs based on the efficacy population.
| Participants | IBRUTINIB/PCI-32765 |
|---|---|
| CLL/SLL | 180 |
| Other NHL | 16 |
| Treatment discontinuation | 3 |
Collected over 8 Years, 5 months. This is a safety longterm follow-up study, it doesn't have any common milestones.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IBRUTINIB/PCI-32765 | 111/199 (55.8%) | 111/199 (55.8%) | 114/199 (57.3%) |
| Event | IBRUTINIB/PCI-32765 |
|---|---|
| PneumoniaInfections and infestations | 32/199 |
| Atrial fibrillationCardiac disorders | 21/199 |
| CellulitisInfections and infestations | 13/199 |
| SepsisInfections and infestations | 11/199 |
| PyrexiaGeneral disorders | 8/199 |
| Urinary tract infectionInfections and infestations | 6/199 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/199 |
| Acute kidney injuryRenal and urinary disorders | 4/199 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/199 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 4/199 |
| Event | IBRUTINIB/PCI-32765 |
|---|---|
| HypertensionVascular disorders | 67/199 |
| Lymphocyte count decreasedInvestigations | 24/199 |
| NeutropeniaBlood and lymphatic system disorders | 21/199 |
| Neutrophil Count decreasedInvestigations | 17/199 |
| CataractEar and labyrinth disorders | 14/199 |
| ThrombocytopeniaBlood and lymphatic system disorders | 10/199 |
| HyperglycemiaMetabolism and nutrition disorders | 10/199 |
| DiarroheaGastrointestinal disorders | 9/199 |
| Upper Respiratory Track InfectionInfections and infestations | 9/199 |
| White Blood cell count decreasedInvestigations | 8/199 |
A total of 199 subjects were enrolled and received at least 1 dose of study treatment and therefore comprised the safety population which was used for safety analyses.
| Age, Categorical(Participants) | A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inh |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 83 |
| >=65 years | 116 |
| Age, Continuous(Years) | A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inh |
|---|---|
| Mean | 65.6 ± 8.98 |
| Sex: Female, Male(Participants) | A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inh |
|---|---|
| Female | 56 |
| Male | 143 |
| Ethnicity (NIH/OMB)(Participants) | A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inh |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 192 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inh |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 8 |
| White | 185 |
| More than one race | 0 |
| Unknown or Not Reported | 3 |
| Region of Enrollment(participants) | A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inh |
|---|---|
| United States | 199 |
| Estimated creatinine clearance rate (mL/min)(ML/min) | A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inh |
|---|---|
| Mean | 85.55 ± 34.150 |
The record gives a start of Jun 2010, a primary completion of Apr 2019 and a completion of Apr 2019. It does not say whether these dates are actual or estimated.
Results were first posted in May 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibrutinib
Leukemia, Lymphocytic, Chronic, B-Cell →